Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme downstream of the cyclooxygenase enzymes, is upregulated by inflammatory stimuli and is involved in the inflammatory processes of cardiovascular diseases and cancer.
Use of mPGES-1 inhibitors in microvascular disease:
Our research has revealed novel uses for mPGES-1 inhibitors in the treatment of microvascular disease and represents a unique opportunity for development of new medicines.
Cardiovascular morbidity and mortality are common in chronic inflammatory diseases due to vascular inflammation and endothelial dysfunction.
Selective deletion of mPGES-1 activity can have several beneficial effects on microvascular disease, such as:
- reduced production of the pro-inflammatory mediator, PGE2
- increased production of vasoprotective prostacyclin
Collectively, these effects lead to anti-inflammatory, vasodilatory and platelet inhibitory benefit to patients.
Use of mPGES-1 inhibitors in cancer:
Recent research has indicated a role of PGE2 in cancer proliferation and immune evasion. Gesynta is currently evaluating this opportunity in collaboration with leading scientists in the fields.